{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:46:03Z","timestamp":1792028763933,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021546","name":"Suez University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021546","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic adenocarcinoma (PAC) is a disease of decimal prognosis, with around 50% of patients presenting with metastatic disease. Previous trials reported a high incidence of early onset pancreatic cancer (EOPAC) in Egypt, presenting about 25% of patients with PAC. The clinic-pathological features and prognosis of EOPAC needs more study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A retrospective analysis of patients\u2019 records at Shefa Al-Orman comprehensive cancer center database. Patients with histo-pathologically confirmed diagnosis of PAC. We categorized patients according to the age at diagnosis into EOPAC (\u2264\u200950 years) and average onset PAC (AOPAC). Data on risk factors, family history, presenting symptoms, clinic-pathological features, treatment, and prognosis were extracted. Patients with histopathologically confirmed diagnosis of pancreatic cancer diagnosed between December 2016-December 2022 were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study cohort consisted of 412 patients. EOPAC represented 20.3% of patients, with no significant differences in risk factors and family history compared to AOPAC. Duration of symptoms before diagnosis is longer in EOPAC, with the majority of EOPAC presenting with localized disease (23.8%) and locally advanced tumors (28.5%) compared to AOPAC. AOPAC presented more with metastatic disease (64% vs. 45.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). EOPAC are usually submitted to more aggressive treatment including radical surgery, neoadjuvant therapy, and aggressive chemotherapy regimens in metastatic disease. Disease free survival (DFS) of EOPAC was shorter than AOPAC (11 months vs. 17 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.889), but overall survival OS was significantly longer in EOPAC (10 months vs. 6 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with EOPAC in Egypt represent around 25% of cases. EOPAC tend to have a shorter disease free survival (DFS) in patients presenting with localized disease. The overall survival (OS) is longer in EOPAC compared to AOPAC. Further studies are mandatory to identify the epidemiological and risk factors of EOPAC in Egypt.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-12955-7","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T03:02:38Z","timestamp":1729220558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Early Onset Pancreatic Adenocarcinoma (EOPAC): presentation, clinical course and treatment outcomes in comparison to Average Onset Pancreatic Adenocarcinoma (AOPAC): a retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3684-9271","authenticated-orcid":false,"given":"Noha","family":"Rashad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa","family":"Sabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam","family":"Alshazly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Samir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"12955_CR1","unstructured":"World Health Organization International Agency for Research on Cancer. GLOBOCAN 2020: pancreatic Cancer fact sheet. Int Agency Res Cancer. 2020:3\u20134."},{"key":"12955_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic Cancer: a review. JAMA - J Am Med Assoc. 2021;326:851\u201362.","journal-title":"JAMA - J Am Med Assoc"},{"key":"12955_CR3","doi-asserted-by":"crossref","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2023;xxx xxx.","DOI":"10.1016\/j.annonc.2023.08.009"},{"key":"12955_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023\u201375.","journal-title":"Lancet"},{"key":"12955_CR5","first-page":"49","volume":"2","author":"J Zhao","year":"2023","unstructured":"Zhao J, Xu L, Sun J, Song M, Wang L, Yuan S, et al. Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019. BMJ Oncol. 2023;2:49.","journal-title":"BMJ Oncol"},{"key":"12955_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2020.10.007","volume":"160","author":"J Huang","year":"2021","unstructured":"Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide Burden of, risk factors for, and trends in Pancreatic Cancer. Gastroenterology. 2021;160:744\u201354.","journal-title":"Gastroenterology"},{"key":"12955_CR7","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1097\/MPA.0000000000000636","volume":"45","author":"H Eguchi","year":"2016","unstructured":"Eguchi H, Yamaue H, Unno M, Mizuma M, Hamada S, Igarashi H, et al. Clinicopathological characteristics of young patients with pancreatic Cancer. Pancreas. 2016;45:1411\u20137.","journal-title":"Pancreas"},{"key":"12955_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00423-019-01810-0","volume":"404","author":"D Ansari","year":"2019","unstructured":"Ansari D, Althini C, Ohlsson H, Andersson R. Early-onset pancreatic cancer: a population-based study using the SEER registry. Langenbeck\u2019s Arch Surg. 2019;404:565\u201371.","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"12955_CR9","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.2147\/OTT.S176700","volume":"12","author":"F Primavesi","year":"2019","unstructured":"Primavesi F, St\u00e4ttner S, Schlick K, Kiesslich T, Mayr C, Klieser E, et al. Pancreatic cancer in young adults: changes, challenges, and solutions. Onco Targets Ther. 2019;12:3387\u2013400.","journal-title":"Onco Targets Ther"},{"key":"12955_CR10","first-page":"139","volume":"176","author":"S Shantanam","year":"2018","unstructured":"Shantanam S. MUELLER. \u4e73\u9f20\u5fc3\u808c\u63d0\u53d6 HHS Public Access. Physiol Behav. 2018;176:139\u201348.","journal-title":"Physiol Behav"},{"key":"12955_CR11","unstructured":"Annals of Gastroent Surgery \u2013\u20092020. - Eguchi - Characteristics of early-onset pancreatic cancer and its association with.pdf."},{"key":"12955_CR12","doi-asserted-by":"publisher","first-page":"7635","DOI":"10.18632\/aging.204310","volume":"14","author":"S Jiang","year":"2022","unstructured":"Jiang S, Fagman JB, Ma Y, Liu J, Vihav C, Engstrom C, et al. A comprehensive review of pancreatic cancer and its therapeutic challenges. Aging. 2022;14:7635\u201349.","journal-title":"Aging"},{"key":"12955_CR13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/jnci\/djab038","volume":"113","author":"AM Varghese","year":"2021","unstructured":"Varghese AM, Singh I, Singh R, Kunte S, Chou JF, Capanu M, et al. Early-onset Pancreas Cancer: clinical descriptors, Genomics, and outcomes. J Natl Cancer Inst. 2021;113:1194\u2013202.","journal-title":"J Natl Cancer Inst"},{"key":"12955_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1385\/IJGC:32:2-3:143","volume":"32","author":"AS Soliman","year":"2002","unstructured":"Soliman AS, El-Ghawalby N, Ezzat F, Bondy ML, Soultan A, Abdel-Wahab M, et al. Unusually high rate of young-onset pancreatic cancer in the East Nile Delta region of Egypt. Int J Gastrointest Cancer. 2002;32:143\u201351.","journal-title":"Int J Gastrointest Cancer"},{"key":"12955_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cdp.2006.06.006","volume":"30","author":"AS Soliman","year":"2006","unstructured":"Soliman AS, Zhang Q, Saleh T, Zarzour A, Selim M, Abdel-Fattah M, et al. Pancreatic cancer mortality in Egypt: comparison to the United States pancreatic cancer mortality rates. Cancer Detect Prev. 2006;30:473\u20139.","journal-title":"Cancer Detect Prev"},{"key":"12955_CR16","doi-asserted-by":"crossref","unstructured":"Baum C, Soliman AS, Brown HE, Seifeldin IA, Ramadan M, Lott B et al. Regional Variation of Pancreatic Cancer Incidence in the Nile Delta Region of Egypt over a Twelve-Year Period. J Cancer Epidemiol. 2020;2020.","DOI":"10.1155\/2020\/6031708"},{"key":"12955_CR17","first-page":"449","volume":"19","author":"MG Abdelrehim","year":"2018","unstructured":"Abdelrehim MG, Mahfouz EM, Ewis AA, Seedhom AE, Afifi HM, Shebl FM. Dietary factors associated with pancreatic cancer risk in Minia, Egypt: principal component analysis. Asian Pac J Cancer Prev. 2018;19:449\u201355.","journal-title":"Asian Pac J Cancer Prev"},{"key":"12955_CR18","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2022.2309","volume":"327","author":"F Keane","year":"2022","unstructured":"Keane F, Du M, O\u2019Reilly EM. Incidence of pancreatic Cancer by Age and Sex in the US from 2000 to 2018. JAMA - J Am Med Assoc. 2022;327:1401\u20132.","journal-title":"JAMA - J Am Med Assoc"},{"key":"12955_CR19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","volume":"4","author":"A Pourshams","year":"2019","unstructured":"Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4:934\u201347.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12955_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3332\/ecancer.2022.1380","volume":"16","author":"H Nassereldine","year":"2022","unstructured":"Nassereldine H, Awada H, Ali AH, Zeineddine M, Sater ZA, Shaib Y. Pancreatic cancer in the MENA region, a bibliometric review. Ecancermedicalscience. 2022;16:1\u201311.","journal-title":"Ecancermedicalscience"},{"key":"12955_CR21","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1016\/S2468-2667(18)30267-6","volume":"4","author":"H Sung","year":"2019","unstructured":"Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Heal. 2019;4:e137\u201347.","journal-title":"Lancet Public Heal"},{"key":"12955_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-018-0866-z","volume":"18","author":"C Ntala","year":"2018","unstructured":"Ntala C, Debernardi S, Feakins RM, Crnogorac-Jurcevic T. Demographic, clinical, and pathological features of early onset pancreatic cancer patients. BMC Gastroenterol. 2018;18:1\u201312.","journal-title":"BMC Gastroenterol"},{"key":"12955_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pan.2015.01.013","volume":"15","author":"M Piciucchi","year":"2015","unstructured":"Piciucchi M, Capurso G, Valente R, Larghi A, Archibugi L, Signoretti M, et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15:151\u20135.","journal-title":"Pancreatology"},{"key":"12955_CR24","doi-asserted-by":"crossref","unstructured":"Adler DG. Pancreatic adenocarcinoma. Atlas Endosc Ultrason Second Ed. 2021:104\u20137.","DOI":"10.1002\/9781119522997.ch22"},{"key":"12955_CR25","doi-asserted-by":"crossref","unstructured":"Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-das A et al. Deleterious Germline Mutations Patients Apparently Sporadic Pancreat Adenocarcinoma. 2017;35.","DOI":"10.1200\/JCO.2017.72.3502"},{"key":"12955_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/1940-6207.CAPR-18-0014","volume":"11","author":"SA Bannon","year":"2018","unstructured":"Bannon SA, Montiel MF, Goldstein JB, Dong W, Mork ME, Borras E, et al. High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer. Cancer Prev Res. 2018;11:679\u201386.","journal-title":"Cancer Prev Res"},{"key":"12955_CR27","doi-asserted-by":"publisher","unstructured":"Fritz CDL, Otegbeye EE, May. https:\/\/doi.org\/10.1093\/jnci\/djad068","DOI":"10.1093\/jnci\/djad068"},{"key":"12955_CR28","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/bjs.10573","volume":"104","author":"MR Thompson","year":"2017","unstructured":"Thompson MR, O\u2019Leary DP, Flashman K, Asiimwe A, Ellis BG, Senapati A. Clinical assessment to determine the risk of bowel cancer using symptoms, Age, Mass and Iron deficiency anaemia (SAMI). Br J Surg. 2017;104:1393\u2013404.","journal-title":"Br J Surg"},{"key":"12955_CR29","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1111\/ans.17698","volume":"92","author":"C Garrett","year":"2022","unstructured":"Garrett C, Steffens D, Solomon M, Koh C. Early-onset colorectal cancer: why it should be high on our list of differentials. ANZ J Surg. 2022;92:1638\u201343.","journal-title":"ANZ J Surg"},{"key":"12955_CR30","first-page":"206","volume":"24","author":"B Tingstedt","year":"2011","unstructured":"Tingstedt B, Weitk\u00e4mper C, Andersson R. Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol. 2011;24:206\u201312.","journal-title":"Ann Gastroenterol"},{"key":"12955_CR31","unstructured":"Journal of Surgical Oncology \u2013\u20092009. - Duffy - Pancreatic adenocarcinoma in a young patient population 12-year experience at.pdf."},{"key":"12955_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11605-012-2066-4","volume":"17","author":"J He","year":"2013","unstructured":"He J, Edil BH, Cameron JL, Schulick RD, Hruban RH, Herman JM, et al. Young patients undergoing resection of pancreatic Cancer Fare Better than their older counterparts. J Gastrointest Surg. 2013;17:339\u201344.","journal-title":"J Gastrointest Surg"},{"key":"12955_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/jamasurg.2014.3572","volume":"150","author":"PJ Kneuertz","year":"2015","unstructured":"Kneuertz PJ, Chang GJ, Hu CY, Rodriguez-Bigas MA, Eng C, Vilar E, et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015;150:402\u20139.","journal-title":"JAMA Surg"},{"key":"12955_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","volume":"31","author":"S Gourgou-Bourgade","year":"2013","unstructured":"Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial. J Clin Oncol. 2013;31:23\u20139.","journal-title":"J Clin Oncol"},{"key":"12955_CR35","doi-asserted-by":"crossref","unstructured":"Fazio N. Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA\/PALB2 -Mutated pancreatic adenocarcinoma: are we moving too fast? J Clin Oncol. 2020:JCO.20.00419.","DOI":"10.1200\/JCO.20.00419"},{"key":"12955_CR36","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/ PALB2 mutation. J Clin Oncol. 2020;38:1378\u201388.","journal-title":"J Clin Oncol"},{"key":"12955_CR37","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","volume":"24","author":"A Sehdev","year":"2018","unstructured":"Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, et al. Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX. Clin Cancer Res. 2018;24:6204\u201311.","journal-title":"Clin Cancer Res"},{"key":"12955_CR38","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38:3217\u201330.","journal-title":"J Clin Oncol"},{"key":"12955_CR39","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2023;34:987\u20131002.","journal-title":"Ann Oncol"},{"key":"12955_CR40","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1158\/1078-0432.CCR-18-3042","volume":"25","author":"I Ben-Aharon","year":"2019","unstructured":"Ben-Aharon I, Elkabets M, Pelossof R, Yu KH, Iacubuzio-Donahue CA, Leach SD, et al. Genomic landscape of pancreatic adenocarcinoma in younger versus older patients: does age matter? Clin Cancer Res. 2019;25:2185\u201393.","journal-title":"Clin Cancer Res"},{"key":"12955_CR41","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1136\/jcp.2005.027292","volume":"59","author":"F Bergmann","year":"2006","unstructured":"Bergmann F, Aulmann S, Wente MN, Penzel R, Esposito I, Kleeff J, et al. Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol. 2006;59:580\u20134.","journal-title":"J Clin Pathol"},{"key":"12955_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13061234","volume":"13","author":"J Raffenne","year":"2021","unstructured":"Raffenne J, Martin FA, Nicolle R, Konta M, Blum Y, Torrisani J, et al. Pancreatic ductal adenocarcinoma arising in young and old patients displays similar molecular features. Cancers (Basel). 2021;13:1\u201318.","journal-title":"Cancers (Basel)"},{"key":"12955_CR43","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/ijc.21986","volume":"119","author":"AS Soliman","year":"2006","unstructured":"Soliman AS, Bondy M, Webb CR, Schottenfeld D, Bonner J, El-Ghawalby N, et al. Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients. Int J Cancer. 2006;119:1455\u201361.","journal-title":"Int J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12955-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12955-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T15:02:47Z","timestamp":1729263767000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12955-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12955"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12955-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted after hospital ethical committee approval and independent review board at Shefaa Al Orman cancer center (SOH-IRB). SOH-IRB registered at the office for human research protections, US department of health& human services and operates under federal wide assurance number FWA 00025406 and its registration number in the Egyptian ministry of health and population is RHDIRB 2017061502. A waiver of informed consent was elaborated by the SOH-IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1289"}}